T he development of unstable atherosclerotic plaques, primarily in the internal carotid artery, but also in the common carotid artery, is a major etiologic factor known to cause strokes. 1 According to the traditional concept of plaque vulnerability, histologically, an unstable plaque is characterized by a large lipid-rich core, a thin fibrous cap with dense inflammatory cell infiltration, ulceration, thrombosis, and intraplaque hemorrhage. 2 The degree of carotid artery stenosis (CAS) is a well-established risk factor of plaque instability and forms the basis for the guidelines for carotid endarterectomy (CEA), a common surgical procedure recommended for stroke prevention. 3 However, more recently, CAS has proven to be an incomplete determinant of plaque instability because even moderate-or low-grade stenoses can be unstable and produce potentially life-threatening strokes. 4, 5 Although several circulating markers (eg, high-sensitivity C-reactive protein and interleukin-6) have emerged as tools for stroke risk assessment in patients with severe carotid atherosclerosis, their ability to reliably and specifically predict plaque instability is suboptimal. 5, 6 Thus, there is a need for novel markers that can accurately identify plaque instability and risk of stroke. such as chemerin, leptin, and resistin, correlate positively with markers of subclinical atherosclerosis, such as carotid intimamedia thickness, and may exert actions that are potentially atherogenic. 7, 8 In contrast, adiponectin, the most abundantly secreted adipokine, exhibits anti-inflammatory and vasculoprotective properties and is inversely associated with carotid intima-media thickness, coronary artery disease, and presence of carotid plaque. [8] [9] [10] [11] [12] As a result, adipokines may serve as potential markers of the presence of carotid atherosclerotic disease. However, their relationship with plaque instability remains questionable. Therefore, the primary objective of this study was to evaluate the association between circulating levels of adiponectin, chemerin, leptin, and resistin and carotid plaque instability in patients with moderate-to highgrade CAS scheduled for CEA. As a secondary objective, we evaluated the association between these adipokines and cerebrovascular symptomatology. We hypothesize that adiponectin will be inversely associated with carotid plaque instability and cerebrovascular symptomatology, whereas the proinflammatory adipokines, chemerin, leptin, and resistin, will have a direct association with both of these outcomes.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
A total of 165 subjects were recruited. Baseline characteristics of the total study population and of the subjects with stable and unstable plaques separately are presented in Table 1 and  in Table I Table 1 ). No other significant differences in terms of patient demographics, clinical variables, adipokine levels (Table 1) , and levels of inflammatory and vascular markers were noted between patients with stable and unstable plaques (Table I in the online-only Data Supplement).
In the nonadjusted Spearman correlation model, age was positively correlated with adiponectin (P=0.002) and resistin levels (P<0.001), whereas body mass index (BMI) correlated negatively with adiponectin (P<0.001) and positively with leptin (P<0.001; Table II in the online-only Data Supplement) . When the correlation model was adjusted for age, sex, and BMI, adiponectin was positively correlated with high-density lipoprotein, and chemerin was positively correlated with high-sensitivity C-reactive protein and negatively with highdensity lipoprotein (Table 2) . No significant correlations were found between levels of adiponectin and the other adipokines.
However, chemerin was correlated positively with leptin and resistin ( Table 2) . Correlations between circulating adipokines and inflammatory and vascular markers are reported in Table  III 
Association of Circulating Adipokines and Carotid Plaque Instability
Adiponectin, leptin, and resistin were not significantly associated with plaque instability, neither in the univariate nor in the multivariate models (Table 3) . Regarding chemerin, the model accounting for age, sex, BMI, and high-sensitivity C-reactive protein and T2DM yielded an odds ratio of 0.942 (95% confidence interval 0.895-1.000) for plaque instability per 10 ng/mL increase in chemerin levels, which corresponds to a 5.8% decrease in the odds of having an unstable plaque. The C statistic associated with this model is 0.685. This association remained significant even after adjustments for circulating adipokine levels, increasing the C statistic to 0.705. Furthermore, in the fully adjusted model (Model 6), there was also a significant 3.0-fold decrease in the odds ratio for plaque instability when the highest tertile of chemerin levels was compared with the lowest (Table 3) .
No significant associations were found between adipokine levels and American Heart Association plaque classification (American Heart Association plaque Type V versus Type VI versus Type VII versus Type VIII; Table IV in the online-only Data Supplement). However, decreased chemerin levels increased the odds of having a Type V (fibroatheroma with a large lipid core) versus a Type VII/Type VIII (predominantly fibrotic/calcific) plaque after adjustments in Model 1 (Table V in the online-only Data Supplement). This association remained significant even after additional adjustments for adiponectin, leptin, and resistin levels (Table V in the online-only Data Supplement).
Adipokine levels were not associated with the degree of CAS (Table VI in the online-only Data Supplement) or with plaque inflammation (data not shown). However, in the multivariate logistic regression models (models 1-6), increased leptin levels were significantly associated with lipid core presence and with increased presence of inflammatory cell cap infiltration ( . BMI indicates body mass index; CAD, coronary artery disease; HbA1C, glycated hemoglobin; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; and T2DM, type 2 diabetes mellitus.
*P value indicates significance between patients with stable and patients with unstable plaques. †Data for HbA1C is reported for n=64 subjects (n=14 subjects with stable phenotype and n=50 subjects with unstable phenotype).
regression analyses in the total population (Table VI in the online-only Data Supplement). However, among subjects with T2DM, resistin levels were significantly elevated in symptomatic versus asymptomatic subjects (P=0.001; Table 4 ) and increased the risk of cerebrovascular symptomatology by 29% (95% confidence interval 1.072-1.561; Table 6 ).
Resistin remained significantly associated with cerebrovascular symptomatology (odds ratio 1.264, 95% confidence interval 1.004-1.594) in subjects with T2DM but not in subjects without T2DM, even after adjustments for age, sex, BMI, and chemerin levels (Table 6 ). However, significance was lost after additional adjustment for leptin (Table 6 ). Furthermore, resistin levels were also noted to be marginally associated with types of cerebrovascular events (P=0.05; Table 5 ), particularly in subjects without T2DM, with highest levels present in patients who had a stroke and lowest levels in those who had an amaurosis fugax (P=0.014; Table 5 ). When comparing patients who underwent CEA within 1 month (14.0 [7.0-21.0] days) versus >1 month (63.0 [42.0-100.5] days) from the cerebrovascular event, no significant differences were observed between circulating adipokines, inflammatory markers, and histological parameters of instability (data not shown).
Discussion
In this study including subjects with moderate-to highgrade CAS scheduled for CEA, we observed that low plasma chemerin levels were associated with increased odds of having an unstable carotid plaque. This association was independent of potential cardiovascular and metabolic confounders. Although not associated with overall plaque instability, leptin levels were increased with the presence of specific histological instability features. Furthermore, in T2DM subjects, high resistin levels were significantly associated with cerebrovascular symptomatology. In contrast, no such associations were observed with the anti-inflammatory protein, adiponectin.
Dual Action of Chemerin
Chemerin is a proinflammatory adipokine whose circulating levels are associated with inflammation and the metabolic syndrome. [13] [14] [15] In line with others, we found high chemerin levels to correlate with T2DM and low high-density lipoprotein. 13, 14 Furthermore, a positive correlation was observed between chemerin and macrophage inflammatory protein 1-α, which is known to be involved in atherogenesis. 15 Although chemerin is less studied than other adipokines in atherosclerosis, a positive and independent association was noted between chemerin and coronary artery disease. 16 Furthermore, a recent study by Zhao et al demonstrated in a Chinese population that subjects with acute ischemic stroke had higher circulating levels of chemerin than those without stroke, and that high levels of chemerin were associated with carotid plaque instability. 17 However, in this smaller study (n=70), carotid plaque instability was determined using Doppler ultrasound. On the contrary, our study, which used the gold-standard histological plaque classifications, [18] [19] [20] is the first to show an independent inverse association between circulating chemerin and carotid plaque instability in CEA subjects with severe carotid stenosis and no significant association with cerebrovascular symptomatology. Although this finding seems to be in contrast with our hypothesis and with previous evidence, 16, 17 it could be partly explained by the dual action (proinflammatory and anti-inflammatory) of chemerin. In addition to adipose tissue, chemerin is also expressed by a number of cell types involved in innate and adaptive immunity and serves as a chemoattractant promoting recruitment of immune cells to sites of injury. 21 However, beyond its proinflammatory role, chemerin also possesses anti-inflammatory properties by inhibiting the production of inflammatory mediators and preventing monocyte adhesion to the vascular endothelium. 22 Chemerin requires cleavage by serine (secreted by neutrophils) or cysteine proteases (released by activated macrophages) to generate a potent and active proinflammatory or anti-inflammatory peptide, respectively. 22, 23 Because neutrophils are the first acting cells at sites of injury or infection, it is likely that proinflammatory chemerin is generated before its anti-inflammatory counterpart. Plaque instability is governed by an increased presence of activated macrophages. 1 Thus, anti-inflammatory chemerin may be produced to control the severity of inflammatory responses associated with unstable plaques, whereas proinflammatory chemerin may be involved in the initial formation and development of atherosclerotic plaques.
Leptin's Proinflammatory Effects on Vascular Cells
Leptin has been demonstrated in experimental studies to play a pathogenic role in atherosclerotic plaque development. 7 Nevertheless, several large prospective epidemiological studies have either demonstrated moderate associations between leptin and coronary heart disease or failed to show an association with incident cardiovascular events. 24, 25 Herein, although circulating leptin levels were not significantly associated with cerebrovascular symptomatology, we reported a positive association between leptin levels and lipid core presence and increased inflammatory cell cap infiltration. In support of this finding, leptin can lead to the upregulation of inflammatory markers, as well as induce the expression of endothelial adhesion molecules, which promote the recruitment, adhesion, and transmigration of leukocytes into the vascular wall. 26 Furthermore, leptin can facilitate the formation of lipid-laden foam cells, which are major contributors of the lipid core.
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Proatherogenic Actions of Resistin
Evidence links elevated resistin levels with atherosclerotic disease. Not only is resistin positively associated with severity of coronary artery disease and calcification, but can also independently predict major cardiovascular events, including ischemic stroke and cardiovascular mortality. [28] [29] [30] [31] Herein, as expected, we identified a significant and independent association between increased resistin levels and cerebrovascular symptomatology. However, this relationship was observed only among T2DM subjects. The positive link between resistin and T2DM has previously been suggested, [32] [33] [34] where T2DM has been reported to strengthen the association between increased ischemic stroke risk and high resistin levels. 35, 36 Resistin was marginally associated with types of cerebrovascular events, particularly in subjects without T2DM and not in subjects with T2DM, where differences were driven by the amaurosis fugax group, with highest resistin levels present in stroke subjects and lowest in patients who had an amaurosis fugax. Considering that we are the first to report resistin levels among subjects who have suffered an amaurosis fugax, it is difficult to explain the differences observed among diabetics and nondiabetics. Because resistin is secreted by macrophages in atherosclerotic plaques, it mediates its proatherogenic effects directly on various cells present in the arterial wall by promoting the expression of inflammatory cytokines and adhesion molecules in the endothelium.
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Adiponectin's Vasculoprotective Properties
Adiponectin plays an important role in lipid and glucose metabolism, improving insulin sensitivity. 40 Furthermore, adiponectin is involved in inflammatory regulation and possesses antiatherosclerotic and vasculoprotective properties. 9, 12 In this context, we found an inverse association between adiponectin and BMI and detected lower levels of circulating adiponectin in T2DM versus non-T2DM subjects. Although we expected to observe a similar association between adiponectin and plaque instability in our patient population, as reported in 2 smaller studies (n≤50), 41, 42 we instead noted no differences in adiponectin levels between patients with stable and unstable carotid plaques. Sawada et al suggested that low adiponectin was the strongest predictor of thin-cap fibroatheroma in men with coronary artery disease, 41 whereas Shido et al showed that subjects with vulnerable carotid plaques had significantly lower adiponectin compared with subjects with stable plaques. 42 In both studies, plaque vulnerability was assessed by imaging methods and not by using the gold-standard histological classifications as in our study. In the circulation, adiponectin forms a trimer, a hexamer, and a high-molecular-weight isoform; the latter is suggested to be the biologically active form, and thus, its measurement may provide a more valuable assessment of the association between adiponectin and plaque instability. 43 Nonetheless, there are several studies that have failed to demonstrate the superiority of high molecular weight over total adiponectin in predicting insulin resistance or atherosclerotic disease. 44, 45 Along with others, we also detected no significant differences in adiponectin levels between symptomatic versus asymptomatic subjects with moderate-to high-grade CAS. 46, 47 Interestingly, it was recently reported that perivascular adiponectin expression, rather than circulating adiponectin, is significantly associated with symptomatology in patients undergoing CEA. Perivascular adipose tissue surrounding symptomatic carotid plaques expressed 1.9-fold higher levels of adiponectin than asymptomatic plaques. 47 This suggests that it may be essential to study adiponectin's local tissue expression rather than its circulating levels in the context of carotid plaque instability and symptomatology.
Traditional Concept of Plaque Vulnerability
The definition of plaque instability used herein, where macrophage-rich plaques characterized by a thin fibrous cap and large lipid-rich core are associated with plaque rupture and subsequent ischemic events, is increasingly becoming recognized as the traditional concept of vulnerability. This is because of evidence demonstrating changes in the morphology and phenotype of the plaque over the past decade. 48, 49 Interestingly, atherosclerotic plaques obtained from recent CEAs were observed to possess more stable features, such as more fibrous tissue and less inflammation, than plaques obtained over a decade ago, despite the significant increase in the proportion of CEAs performed on symptomatic subjects. 49 These changes are partly believed to be associated with improvements in risk factor management. In our own study, plaque instability was not associated with cerebrovascular symptomatology; a relatively high proportion of stable plaques were found to be symptomatic (64.6%), only ≈10% lower than unstable plaques (76.1). This cannot be attributed to the timing of the CEA, given that the vast majority of the subjects (60.7%) underwent a CEA within the first month after the event (14.0 [7.0-21.0] days). Of note, most subjects who had symptomatic stable plaques experienced symptoms caused by a transient ischemic attack, whereas a greater majority of subjects who had symptomatic unstable plaques had a stroke rather than a transient ischemic attack. Nevertheless, it is important to keep in mind for future studies that the current concept of plaque vulnerability may need to evolve with the recent observed changes in the histopathologic features of plaques, which are presently believed to be causal for plaque instability.
Limitations
Our study has certain limitations. Because of the cross-sectional design of this study, the direction of causality between the circulating adipokines and plaque instability or cerebrovascular symptomatology cannot be inferred. However, because specimens are necessary for the assessment of plaque instability, we need to obtain tissue from patients with moderate-to highgrade CAS, which can only be obtained at a single time point, at the time of CEA. Although we acknowledge that the lack of prospective data limits the establishment of the true diagnostic potential of circulating chemerin and resistin in predicting plaque instability or stroke risk, our study acts as the first phase (proof-of-concept phase) in the evaluation of novel biomarkers.
Thus, in the future, it would be necessary to perform prospective studies following patients with early carotid plaques to determine whether circulating adipokines are associated with the development of unstable carotid plaques. Furthermore, in our study, we only assessed the independence of individual adipokines in predicting plaque instability and cerebrovascular symptomatology. However, the identification of a panel of markers may provide greater predictive value and reliability than a single marker. 5, 6 Second, although not the aim of our study, we did not provide any insights into the biological significance of the adipokines in question, in relation to atherosclerotic lesions, which would have greatly increased the impact of the study. However, our next steps will focus on addressing potential mechanisms in a future experimental study. Finally, the semiquantitative analysis of the carotid plaques as stable or unstable is a limitation of the study. However, Stary and Lovett's histological classifications [18] [19] [20] were used because they are validated scales that are widely established and represent the gold-standard for classifying the instability of atherosclerotic plaques. Classifications using quantitative image analysis are promising methods for categorization of plaque instability; however, they need to be validated for wide-spread use against the gold-standard methods used herein.
Conclusions
To the best of our knowledge, this study including a large number of carotid endarterectomies was the first to assess the relationship between circulating adipokine levels and carotid plaque instability as evaluated via gold-standard histological classifications. Our study highlights an association between chemerin and plaque instability in CEA subjects with moderate-to high-grade CAS, whereas high leptin levels were associated with certain histological instability features. Although no relationship was observed between resistin and plaque instability, among T2DM subjects, high resistin levels were associated with cerebrovascular symptomatology. Future studies are needed to elucidate the additive role of chemerin and resistin to that of traditional risk factors and the degree of CAS in the prediction of plaque instability and in the development of cerebrovascular symptomatology. Furthermore, assessment of the local plaque expression of these adipokines may provide evidence on the human pathophysiological mechanisms linking adipokines and plaque instability.
